Summary
Canagliflozin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 2 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 2 Diabetes. ClinicalTrials.gov lists 8 registered trials linking Canagliflozin to Type 2 Diabetes: 1 is active or not yet recruiting; 6 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT02653209). The largest enrolment is 1299 participants (NCT01387737). Registration activity spans 2005 to 2024. The literature layer holds 11 publications for this pair: 5 Cochrane reviews, 1 meta-analysis and 5 clinical trial publications. The dated items are from 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Type 2 Diabetes Mellitus ranks 767 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 1.6-1.7% at 7 years on standard care (population-level cohorts UK and US).
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 80.0 (trials 30.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 1 active / not yet recruiting, 6 completed, 1 other |
| Linked publications | 11 (5 Cochrane reviews, 5 clinical trial publications, 1 meta-analysis) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07325435 | Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists 2024 | active, not recruiting | Phase 4 | 60 |
| NCT02653209 | TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. 2016 | completed | Phase 4 | 525 |
| NCT02142309 | Glycemic Durability After Metformin Failure 2005 | status unknown | Phase 4 | 450 |
| NCT01387737 | Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus 2011 | completed | Phase 3 | 1,299 |
| NCT01106625 | The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea) 2010 | completed | Phase 3 | 469 |
| NCT01340664 | An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy 2011 | completed | Phase 2 | 279 |
| NCT02737657 | An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan 2016 | completed | Not applicable | 379 |
| NCT03422263 | Performance Under SGLT-2-Inhibitors in Humans 2018 | completed | Not applicable | 450 |
Published literature
- Clinical trial publication Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney diseaseLong W, Ningning L, Weijun H · Pakistan journal of pharmaceutical sciences · 2026 · PMID 42170981
- Clinical trial publication Effects of mulberry twig alkaloids and canagliflozin in inadequately controlled type 2 diabetes: a randomized controlled study based on flash glucose monitoringLi H, Tao S, Zhou X et al. · Scientific reports · 2026 · PMID 42014890
- Clinical trial publication Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trialChiriacò M, Tricò D, Giannoni A et al. · Diabetologia · 2026 · PMID 41817689
- Clinical trial publication Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trialYan H, Liu J, Zhang Z et al. · Diabetologia · 2026 · PMID 41735586
- Clinical trial publication Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE TrialsMoedt E, Coca SG, Edwards K et al. · Diabetes care · 2026 · PMID 41217780
- Cochrane review Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trialsGao S, Zhang F, Xie X et al. · Frontiers in endocrinology · 2026 · PMID 42211460
- Cochrane review Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysisZhu X, Wang X, Zhang P et al. · Frontiers in endocrinology · 2026 · PMID 41987895
- Cochrane review Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic reviewWang L, Wang Y, Zhao Q · European journal of clinical pharmacology · 2026 · PMID 41811375
- Cochrane review Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-AnalysisKumari K, Bai A, Geeta F et al. · Endocrinology, diabetes & metabolism · 2026 · PMID 41777041
- Cochrane review The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysisZeng BS, Chen JJ, Hsu CW et al. · Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026 · PMID 41610949
- Meta-analysis Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-AnalysisSridharan K, Sivaramakrishnan G · Medical sciences (Basel, Switzerland) · 2026 · PMID 41892868
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Canagliflozin approved for Type 2 Diabetes?
Canagliflozin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 2 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 2 Diabetes. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Canagliflozin in clinical trials for Type 2 Diabetes?
ClinicalTrials.gov lists 8 registered trials linking Canagliflozin to Type 2 Diabetes: 1 is active or not yet recruiting; 6 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT02653209). The largest enrolment is 1299 participants (NCT01387737). Registration activity spans 2005 to 2024.
What does the evidence show for Canagliflozin in Type 2 Diabetes?
Canagliflozin has both completed registered trials and synthesis-level publications linked to Type 2 Diabetes. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.